VEGF inhibition by bevacizumab can also restore the function and enhance the infiltration of effector T cells, decrease the number of immunosuppressive Tregs, tumor associated macrophages (TAMs), and mast cells, and inhibit the accumulation and immunosuppressive activity of myeloid-derived suppressor cells (MDSCs). This evidence concerns the gene VEGFA and neoplasm.